Multitargeted Receptor Tyrosine Kinase Inhibitor AP24534
Cancer Terms ->
Drugs and Chemicals ->
Pharmacologic Substance ->
Enzyme Inhibitor ->
Protein Kinase Inhibitor ->
Tyrosine Kinase Inhibitor -> Multitargeted Receptor Tyrosine Kinase Inhibitor AP24534
Multitargeted Receptor Tyrosine Kinase Inhibitor AP24534 Definition
An orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Multitargeted tyrosine kinase inhibitor AP24534 inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). RTK inhibition by AP24534 may result in the the inhibition of cellular proliferation and angiogenesis and may induce cell death. Bcr-Abl is a fusion tyrosine kinase encoded by the Philadelphia chromosome.
Multitargeted Receptor Tyrosine Kinase Inhibitor AP24534 Synonyms
Multitargeted Tyrosine Kinase Inhibitor AP24534, AP24534
Terms in Multitargeted Receptor Tyrosine Kinase Inhibitor AP24534 category
Copyright © Cancer Terms 2014 All rights reserved. | Terms of Use | Low Carb Foods
No reproduction or republication permitted.